Minjie Zhang

6PUBLICATIONS
113CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

|Apr 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers.

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|Jun 24, 2025
MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models.

Xiaochun Zhang, Dana C Borcherding, Minjie Zhang

|Oct 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.

Antoine Simoneau, Justin L Engel, Madhavi Bandi

|Sep 07, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.

Julie A Shields, Samuel R Meier, Madhavi Bandi

Pageof 1

Frequent Collaborators

6 joint publications

Alan Huang

5 joint publications

Jannik N Andersen

5 joint publications

John P Maxwell

4 joint publications

Douglas A Whittington